ARCT Share Price Performance
US$6.63
-7.53 (-53.18%)
5.3% undervalued intrinsic discount
US$7.00
Fair Value
Price US$6.63
AnalystLowTarget US$7.00
AnalystHighTarget US$72.00
Fair ValueUS$7.00
Share Pricen/a
Arcturus Therapeutics Holdings Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 72 Fair Values set on narratives written by author
ARCT Community Narratives
AN
Fair Value US$7 5.3% undervalued intrinsic discount
Revenues Will Fall And Pipeline Risks Will Hinder RNA Upside
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$72 90.8% undervalued intrinsic discount
Self-amplifying mRNA Will Meet Aging Global Therapy Demand
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Revenues Will Fall And Pipeline Risks Will Hinder RNA Upside
Key Takeaways Heavy reliance on a few clinical programs and uncertain commercialization timelines create considerable risk for sustained revenue and earnings growth. Elevated cash burn, history of losses, and potential delays in partnerships heighten the risk of future dilution or unprofitable expansion.Read more
58
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$7
5.3% undervalued intrinsic discount
Fair Value
Profit Margin
10.9%
Future PE
54.08x
Price in 2029
US$8.46
Self-amplifying mRNA Will Meet Aging Global Therapy Demand
Key Takeaways Unique mRNA platform enables rapid market expansion and premium positioning in vaccines, with strong potential for high-margin, recurring revenues and first-mover advantages. Operational efficiency and breakthrough pipeline support sustainable growth, while industry trends drive significant partnering and shareholder value-creation opportunities.Read more
80
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$72
90.8% undervalued intrinsic discount
Fair Value
Profit Margin
66.14%
Future PE
5.56x
Price in 2028
US$87
Trending Discussion
Recently Updated Narratives
AN
ARCT: Elevated Future P/E Assumptions Will Pressure Execution Risk Outlook
Fair Value: US$7 5.3% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ARCT: Orphan mRNA Cystic Fibrosis Program Will Drive Future Upside
Fair Value: US$72 90.8% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Arcturus Therapeutics Holdings Inc. Key Details
About ARCT
- Founded
- 2013
- Employees
- 109
- CEO
- WebsiteView website
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
